Last reviewed · How we verify
Isindone (INDOPROFEN)
Indoprofen (Isindone) is a marketed drug that uniquely inhibits the pyruvate kinase PKM enzyme, setting it apart in the NSAID class. Its key strength lies in its distinct mechanism of action, which differentiates it from competitors such as ibuprofen, naproxen, ketoprofen, and fenoprofen, all of which are either off-patent or have significant generic competition. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | INDOPROFEN |
|---|---|
| Drug class | indoprofen |
| Target | Pyruvate kinase PKM, Fatty acid-binding protein, liver, Luciferin 4-monooxygenase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 1979 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isindone CI brief — competitive landscape report
- Isindone updates RSS · CI watch RSS